DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Hepatic - Colorectal Metastasis - Pipeline Review, H1 2017" report to their offering.
Hepatic - Colorectal Metastasis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatic - Colorectal Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hepatic - Colorectal Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatic - Colorectal Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 2 and 4 respectively.
Hepatic - Colorectal Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Hepatic - Colorectal Metastasis - Overview
- Hepatic - Colorectal Metastasis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Hepatic - Colorectal Metastasis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hepatic - Colorectal Metastasis - Companies Involved in Therapeutics Development
- Alfact Innovation
- Cellular Biomedicine Group Inc
- Delcath Systems Inc
- Gradalis Inc
For more information about this report visit http://www.researchandmarkets.com/research/8zxqcw/hepatic